A Gut Feeling for Metformin.
Level V
Where this comes from
- Record sourced from PubMed, PMID 30517894.
- Also identified by DOI 10.1016/j.cmet.2018.11.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metformin is a first-line glucose-lowering agent in patients with type 2 diabetes (T2D). Recently in Nature Medicine, Sun et al. (2018) reported that short-term metformin therapy decreases gut Bacteroides fragilis, consequently increasing glycoursodexoycholic acid (GUDCA) levels in humans. As an antagonist of FXR, GUDCA may carry therapeutic potential in the treatment of T2D.
Medical subject headings
- Diabetes Mellitus, Type 2
- Gastrointestinal Microbiome
- Metformin